Drug Profile
Research programme: topical antibacterial and anti-inflammatory therapeutics - SALVAT
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator SALVAT
- Class
- Mechanism of Action Keratinocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Psoriasis; Skin and soft tissue infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Psoriasis in Spain (Topical)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in Spain (Topical)
- 31 Mar 2011 Preclinical development is ongoing for Skin infections and Psoriasis in Spain